3 recruiting, 1 completed, 1 unknown. 5 Phase 3, 1 Phase 2.
By phase and status
Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL
Trials (filtered) newest first · largest first
All 5 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Tafasitamab, Lenalidomide, Gemcitabine - DLBCL Phase 3 Recruiting 244 2024-05-07 2024-07-25 A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) Zilovertamab vedotin, Rituximab, Gemcitabine - DLBCL, Diffuse Large B-Cell Lymphoma Phase 2 / Phase 3 Recruiting 290 2022-01-14 2026-11-03 A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma R-pola-mini-CHP, R-mini-CHOP - DLBCL, Diffuse Large B Cell Lymphoma Phase 3 Recruiting 300 2020-08-19 2024-09-19 High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL Intrathecal methotrexate, High-dose intravenous methotrexate - DLBCL Phase 3 Unknown 205 2017-07-01 2017-04-24 Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients RCHOP21 - DLBCL Phase 3 Completed 650 2010-12-01 2020-07-14
Narrower conditions Lymphoma, Large B-Cell, Diffuse (2)
Broader conditions Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
Interventions Gemcitabine (2) · Oxaliplatin (2) · Rituximab (2) · Bendamustine Hydrochloride (1) · Granulocyte Colony-Stimulating Factor (1) · Lenalidomide (1) · tafasitamab (1)
Sponsors Beijing InnoCare Pharma Tech Co., Ltd. (1) · Chonnam National University Hospital (1) · Merck Sharp & Dohme LLC (1) · Nordic Lymphoma Group (1) · The Lymphoma Academic Research Organisation (1)
Countries Australia (2) · China (2) · Denmark (2) · France (2) · Italy (2) · New Zealand (2) · South Korea (2) · Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Costa Rica (1) · Finland (1)
Top investigators Mats Jerkeman (1) · Serge Bologna, MD (1)
Results publications PMID 41260259